Satish Garg

Valeritas, Inc. engages in the development and commercialization of drug delivery solutions for the treatment of diabetes. Its product, V-Go wearable insulin delivery device, which enables patients to closely mimic the body’s normal physiologic pattern of insulin delivery by using one type of insulin at a continuous preset basal rate over a 24-hour period and provides on-demand bolus dosing for meals and snacks. The company was founded on August 2, 2006 and is headquartered in Bridgewater, NJ.